A detailed history of Stanley Druckenmiller (Duquesne Family Office LLC) transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Duquesne Family Office LLC holds 571,425 shares of ADGI stock, worth $1.89 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
571,425
Holding current value
$1.89 Million
% of portfolio
0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
N/A
571,425 New
571,425 $629,000

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track Stanley Druckenmiller's Portfolio

Track Stanley Druckenmiller Portfolio

Follow Stanley Druckenmiller (Duquesne Family Office LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

News

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.